Literature DB >> 8750802

Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts.

D Klement1, S Rammos, R v Kries, W Kirschke, H W Kniemeyer, A Greinacher.   

Abstract

UNLABELLED: A 15-year-old boy developed deep vein thrombosis of the right leg 9 days after appendectomy. In spite of three courses of thrombolysis with streptokinase and effective heparinization the thrombosis progressed with additional occlusion of the left iliac vein. Although platelet counts were constantly normal, heparin-associated thrombocytopenia was suspected as the cause of the new venous occlusions. This diagnosis was confirmed by detecting heparin-associated antibodies with the heparin-induced platelet activation test. Therapy was instituted replacing heparin by the low molecular weight heparinoid Orgaran. Bilateral recanalization occurred within 6 days.
CONCLUSION: Heparin-associated thrombocytopenia must be considered if thrombosis occurs or progresses despite effective heparinization even in the absence of thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750802     DOI: 10.1007/bf02115618

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

Review 2.  [The therapy of heparin-associated thrombocytopenia].

Authors:  A Greinacher; C Mueller-Eckhardt
Journal:  Dtsch Med Wochenschr       Date:  1991-09-27       Impact factor: 0.628

Review 3.  [The diagnosis of heparin-associated thrombocytopenia].

Authors:  A Greinacher; C Mueller-Eckhardt
Journal:  Dtsch Med Wochenschr       Date:  1991-09-27       Impact factor: 0.628

4.  Heparin-associated thrombosis without thrombocytopenia.

Authors:  B K Phelan
Journal:  Ann Intern Med       Date:  1983-11       Impact factor: 25.391

Review 5.  Heparin-associated thrombocytopenia.

Authors:  D J King; J G Kelton
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

6.  Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.

Authors:  A Greinacher; J Amiral; V Dummel; A Vissac; V Kiefel; C Mueller-Eckhardt
Journal:  Transfusion       Date:  1994-05       Impact factor: 3.157

7.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

8.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.

Authors:  A Greinacher; W Drost; I Michels; J Leitl; M Gottsmann; H J Kohl; M Glaser; C Mueller-Eckhardt
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 10.  Heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739

View more
  10 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

Authors:  T E Warkentin
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

Review 4.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 5.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes.

Authors:  Lorenz Risch; Joachim E Fischer; Roberto Herklotz; Andreas R Huber
Journal:  Intensive Care Med       Date:  2004-05-19       Impact factor: 17.440

7.  Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases.

Authors:  Rosalia Porcelli; Bonnie C Moskowitz; Frank Cetta; Lynn C Graham; John E Godwin; Benjamin W Eidem; M Margaret Prechel; Jeanine M Walenga
Journal:  Tex Heart Inst J       Date:  2003

8.  Stent thrombosis caused by metal allergy complicated by protein S deficiency and heparin-induced thrombocytopenia: a case report and review of the literature.

Authors:  Takao Konishi; Tadashi Yamamoto; Naohiro Funayama; Beni Yamaguchi; Seiichiro Sakurai; Hiroshi Nishihara; Koko Yamazaki; Yusuke Kashiwagi; Yasuki Sasa; Mitsuru Gima; Hideichi Tanaka; Daisuke Hotta; Kenjiro Kikuchi
Journal:  Thromb J       Date:  2015-07-23

9.  Commentary: Getting HIT with HIT minus T (thrombosis without thrombocytopenia).

Authors:  Frank Edwin; Mark Mawutor Tettey; Martin Nartey Tamatey
Journal:  JTCVS Open       Date:  2020-08-29

10.  Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement.

Authors:  Takafumi Torigoshi; Satoru Motokawa; Yumi Maeda; Kazushige Maeda; Takeshi Hiura; Gou Takayama; Kenji Taguchi; Hiroyuki Shindo; Kiyoshi Migita
Journal:  BMC Musculoskelet Disord       Date:  2009-04-28       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.